Pam Cheng

NORTH BETHESDA, Md. (PRWEB)
August 11, 2023

The International Society for Pharmaceutical Engineering (ISPE) announced eight keynote speakers for the 2023 ISPE Annual Meeting & Expo, occurring 15-18 October in Las Vegas, NV, and virtually. This acclaimed event brings together top pharmaceutical industry and regulatory leaders, offering compelling presentations and interactive discussions on industry-critical technical developments.

The 2023 ISPE Annual Meeting & Expo features a dynamic line-up of thought-provoking keynote presentations led by some of the most prominent names in the pharmaceutical industry.

Confirmed Keynote Speakers:

Pam Cheng – Executive Vice President, Global Operations and Information Technology – AstraZeneca

Pam Cheng is the Executive Vice President, Global Operations and Information Technology, and Chief Sustainability Officer for AstraZeneca. She led AstraZeneca’s Global Operations in developing and supplying 3 billion COVID-19 vaccine doses to more than 170 countries. With oversight across 18 countries, Pam manages manufacturing, supply chain, procurement, IT, and sustainability, leading a team of over 20,000. Prior, she spent 18 years at Merck/MSD in global roles. Pam holds bachelor’s and master’s degrees in chemical engineering from Stevens Institute of Technology and an MBA in marketing from Pace University.

Judy Chou – President and CEO – AltruBio, Inc

Judy Chou, PhD is the CEO, President, and board member of AltruBio, Inc., a clinical-stage biotech company in San Francisco, CA. With a remarkable career in the biomedical industry, she has led global biotech organizations, including Bayer Pharmaceuticals. Judy’s expertise lies in the development and manufacturing of biologics, and she has made significant contributions to breakthrough technologies and accelerated product development. She serves on the boards of Akero Therapeutics, Inc., California Institute of Regenerative Medicines (CIRM), and advisory boards for UC Berkeley Engineering School and Silicon Valley Women in Engineering.

David Churchward – Global Head Sterility Assurance, Cell and Gene Technologies – Lonza Biologics

David Churchward is the Global Head of Sterility Assurance for Lonza Biologics’ cell and gene technologies business unit. With extensive experience in regulatory collaboration and international harmonization, David ensures sterility assurance standards for manufacturing cell therapies and viral vector products. He previously served as a GMP inspector with the UK MHRA and contributed to major regulatory initiatives.

Kyle Haraldsen – Chief Technology Officer – Lyndra Therapeutics

Kyle Haraldsen is the Chief Technology Officer of Lyndra Therapeutics. With over 20 years of industry experience, he leads product and platform R&D activities, including the development of the LYNX™ drug delivery platform. Kyle has a strong background in technical operations, product development, and project management, having held leadership positions at Saniona and AMAG Pharmaceuticals.

Celia Lourenco – Acting Associate Assistant Deputy Minister – Health Canada

Celia Lourenco, PhD, is the Acting Associate Assistant Deputy Minister for the Health Products and Food Branch of Health Canada. With extensive experience in drug regulation, Celia provides strategic direction for health product and food regulation. She has engaged with international regulatory authorities and co-chaired the COVID-19 working group at the International Coalition of Medicines Regulatory Authorities.

Flavius Martin – Executive Vice President of Research – Gilead Sciences, Inc

Flavius Martin is the Executive Vice President of Research at Gilead Sciences, Inc. In this role, he oversees innovative research and preclinical programs across therapeutic areas. With nearly 20 years in the biopharmaceutical industry, Flavius has held leadership positions at Amgen and Genentech, contributing to advancements in oncology, inflammation, and cardiometabolic research.

Matthew Pearl – Patient Advocate – Fanconi Anemia Research Fund & EveryLife Foundation

Matthew Pearl is a remarkable patient advocate and a dedicated contributor to various nonprofits who captivates audiences worldwide, sharing his invaluable insights and inspiring the Rare Disease Community. His commitment extends to organizations such as the Fanconi Anemia Research Fund, the Rare Action Network, the National Organization for Rare Disorders, and the National Ability Center. Matthew’s groundbreaking research at the Dana Farber Cancer Institute at Harvard, where he was the first Fanconi Anemia (FA) patient to investigate FA, has garnered international recognition.

Michael Lee Sherwood – Chief Innovation and Technology Officer – City of Las Vegas

Michael Lee Sherwood has over 20 years of experience in process improvement, technology, and innovation. As the Chief Innovation and Technology Officer for the City of Las Vegas, he drives initiatives to create brighter and more sustainable communities through collaboration and workforce development. Michael previously served as the Deputy Director of Public Safety, Business Services & City Technology for the City of Irvine, California.

Learn more and register for the 2023 ISPE Annual Meeting & Expo today.

About ISPE

The International Society for Pharmaceutical Engineering (ISPE) is a global nonprofit association serving its members through leading scientific, technical, and regulatory advancement across the entire pharmaceutical lifecycle. The 20,000+ members of ISPE provide solutions to complex pharmaceutical industry challenges through innovation, member and workforce development, and technical, regulatory, and compliance collaborations in more than 120 countries worldwide. Founded in 1980, ISPE has its worldwide headquarters and training center in North Bethesda, Maryland, USA, and its operations center in Tampa, Florida, USA. For more information, visit ISPE.org.

Share article on social media or email:

David J. Galas, Ph.D.

“WRF’s generous gift is a profound testament to David, who never stopped discovering and pushed the boundaries of our knowledge about genetics right up to the end of his life.” Diane Isonaka

SEATTLE (PRWEB)
August 10, 2023

Washington Research Foundation (WRF) has awarded a $100,000 grant to Pacific Northwest Research Institute (PNRI) in honor of David J. Galas, Ph.D., who helped to create the WRF Postdoctoral Fellowship program in 2017 and served on the WRF board of directors from 2010 until his death in May. The grant will support the continuation of work begun by Galas and his colleague Lisa Stubbs, Ph.D., investigating the genetic links between stress and a range of health disorders.

Galas was a renowned expert in molecular biology and human genetics. He was a leader in the Human Genome Project and a key contributor to the technology that enabled one of the earliest rapid tests for COVID-19. In 2012, he joined PNRI as a senior investigator.

Inspired to apply his novel computational approaches to find ways to improve the human condition, Galas, together with PNRI senior investigator Stubbs, launched the groundbreaking Decoding Stress Study in 2021. The goal of the study is to pinpoint the exact genes, gene networks and patterns of mutations responsible for how humans’ brains and bodies respond to chronic stress and to identify how an individual’s unique genetic makeup contributes to their risk of developing stress-related diseases, such as anxiety, depression, type 2 diabetes and heart disease.

Galas and his team focused on developing and applying innovative mathematical methods, providing new computational tools to seek out and validate genetic interactions significant to this research. The findings of the Decoding Stress Study will ultimately provide the basis for new genetic screens to identify people who are at the greatest risk of developing stress-related disease, as well as to guide doctors in choosing the right treatment for each person.

With support from WRF’s grant, Stubbs will continue to lead this project.

“We are honored to continue pursuing David’s vision—that of using an individual’s unique genetic make-up to identify those at greatest risk of stress-related diseases—with the goal of developing tailored therapies to identify and treat them. This is David’s legacy gift to all humanity,” said Stubbs.

In addition to his roles with PNRI and WRF, Galas was chair of the Hertz Foundation board of directors, a lifetime National Associate of the National Academy of Sciences, and an entrepreneur who held 20 issued U.S. patents and authored more than 180 scientific publications. He was also an accomplished artist and poet.

Brooks Simpson, WRF’s board chair, said, “David was an incredible board member and mentor to all of us. We are better board members, stronger staff and an enriched organization because of him. As an example, David’s insight and belief in postdocs led to the creation of our fellowship program. That will always remain a hallmark of our contributions to the research engines in the region.”

“WRF’s generous gift is a profound testament to David, who never stopped discovering and pushed the boundaries of our knowledge about genetics right up to the end of his life,” said Diane Isonaka, Galas’ widow. “This gift will ensure that the innovative methods and tools that David introduced in the Decoding Stress Study will continue to shape the field of genetics and benefit generations to come with improved healthcare, personalized treatments and a deeper understanding of life itself.”

###

About Pacific Northwest Research Institute:

Pacific Northwest Research Institute (PNRI) is a nonprofit biomedical research institute, where scientists use innovative approaches in genetics and genomics to tackle some of the most difficult problems in science and medicine. The institute was founded 67 years ago in Seattle, Washington, as a place where scientists were free to pursue discoveries that promised the highest chance of improving human health. The goal was at the beginning, and remains today, to conduct foundational science that drives future medical innovations. To learn more, visit pnri.org.

About Washington Research Foundation:

Washington Research Foundation (WRF) supports research and scholarship in Washington state, with a focus on life sciences and enabling technologies. WRF was founded in 1981 to assist universities and other nonprofit research institutions in Washington with the commercialization and licensing of their technologies. WRF is one of the foremost technology transfer and grant-making organizations in the nation, having earned more than $445 million in licensing revenue for the University of Washington and providing over $147 million in grants to the state’s research institutions to date.

WRF Capital, the investment vehicle for Washington Research Foundation, has backed 122 local startups since 1996. Returns support the Foundation’s investment and grant-making programs.

For additional information, please visit wrfseattle.org.

Share article on social media or email:

RNs earn the CTRN credential to demonstrate mastery of advanced clinical and professional knowledge in critical care ground transport nursing. The CTRN is BCEN’s fastest growing certification program.

Excellence in ground transport nursing is crucial to the public emergency response and successful interfacility transfers of critically ill and injured patients. ABSNC accreditation of the CTRN … is an important signal to nurses, healthcare teams, institutions, and patients and their families.

OAK BROOK, Ill. (PRWEB)
August 10, 2023

The Board of Certification for Emergency Nursing, the benchmark for specialty excellence across the emergency nursing spectrum, today announced that its Certified Transport Registered Nurse (CTRN) national board certification program for critical care ground transport nurses has been accredited by the Accreditation Board for Specialty Nursing Certification (ABSNC). Accreditation by ABSNC means that the CTRN certification program has met or exceeds the nursing certification industry’s most rigorous standards based on an independent, peer-reviewed process.

RNs play a major role in delivering crucial and often life-preserving or life-saving care to critically ill or injured patients in the dynamic, autonomous and high stakes ground transport environment. To earn the CTRN credential, nurses must demonstrate mastery of advanced ground transport nursing-specific clinical knowledge as well as safety, survival, disaster preparedness, scene operations management, communications, and equipment and vehicle knowledge.

“Excellence in ground transport nursing is crucial to the public emergency response and successful interfacility transfers of critically ill and injured patients,” said BCEN CEO Janie Schumaker, MBA, BSN, RN, CEN, CPHQ, CENP, FABC. “ABSNC accreditation of the CTRN ground transport specialty certification is an important signal to nurses, healthcare teams, institutions, and patients and their families alike.”

The CTRN is BCEN’s fastest growing certification program, increasing by 19% in 2020, 29% in 2021, and 24% in 2022 as well as in 2023 year-to-date. According to a peer-reviewed January/February 2023 Air Medical Journal article, the top three perceived benefits of holding the CTRN are critical thinking in the ground transport environment (88%), confidence as a ground transport nurse (88%), and a sense of accomplishment and pride (95%). Over half (51%) of survey respondents reported doing more ground transports since the start of the pandemic, and nearly two-thirds (62%) said being a CTRN “contributed to their ability to deliver the best possible care” to patients with COVID-19.

“To earn initial accreditation, a certification body must provide detailed data that demonstrates a particular certification program adheres to ABSNC’s 18 accreditation standards including organizational autonomy, basis in a body of research-based knowledge, nondiscrimination, test development, validity, reliability, test administration, test security, fairness of passing score, recertification, and confidentiality,” said BCEN Director of Certification and Accreditation Amy Grand, MSN, RN, ICE-CCP . “We are proud to say that all five of BCEN’s currently available certification programs are now accredited.” BCEN’s new burn nursing credential will launch in Q4 2023.

Additionally:

• The CTRN has been ANCC Magnet-accepted since 2009.
• The Commission on Accreditation of Medical Transport Systems (CAMTS) has recognized the CTRN since 2006 and now requires that RNs hold a transport-specific credential.
• While the number of CTRNs has grown steadily since the credential was introduced in 2006, the number of CTRNs has doubled in just the past three years. Today, over 500 nurses hold the CTRN.

For more on the CTRN and ground transport nursing, read “The Roles and Contributions of Certified Transport Registered Nurses in Critical Care Ground Transport Today” in the March 2022 Air Medical Journal and “Grounded in Excellence: The CTRN“.

For more about ABSNC, the only accrediting body specifically for nursing certifications, and to read ABSNC’s announcement regarding initial accreditation of the CTRN, please visit absnc.org.

About BCEN

Founded in 1980, the independent, not-for-profit Board of Certification for Emergency Nursing (BCEN®) offers robust certification programs fostering empowered nurses across the emergency spectrum who contribute noticeably to patient care, safety and outcomes. Over 59,000 BCEN board certifications are held by registered nurses (RNs) who specialize in emergency, flight, critical care ground transport, pediatric emergency, and trauma nursing. BCEN offers the Certified Emergency Nurse (CEN®), Certified Flight Registered Nurse (CFRN®), Certified Pediatric Emergency Nurse (CPEN®), Certified Transport Registered Nurse (CTRN®) and Trauma Certified Registered Nurse (TCRN®) certifications, all of which are accredited by ABSNC. BCEN’s newest certification, the Certified Burn Registered Nurse (CBRN), will be widely available in Q4 2023. Learn more at bcen.org. Follow BCEN on Facebook, LinkedIn and Instagram.

# # #

Share article on social media or email:

Dr. An Nguyen, McGovern Allergy & Asthma Clinic

“I chose to become an allergist because it allows me to work with patients of all ages and address a wide range of medical issues associated with immune system dysregulation.” – Dr. An Nguyen, McGovern Allergy & Asthma Clinic

HOUSTON (PRWEB)
August 10, 2023

Dr. An Nguyen is making significant strides in Allergy and Immunology with her extensive educational background and dedication to providing comprehensive and personalized treatment to individuals of all ages. Dr. Nguyen obtained her doctorate from UT Southwestern and further specialized in Internal Medicine during her Baylor College of Medicine residency. Her relentless pursuit of knowledge led her to complete a fellowship in Allergy and Immunology at the same prestigious institution. During her fellowship, Dr. Nguyen focused on groundbreaking research, investigating the role of vitamin D in the immunomodulation of allergic disease and the impact of fungi on sinus disease and asthma. Inspired by her experience with allergies and eczema, Dr. Nguyen chose to specialize in Allergy and Immunology. She believes that her journey enables her to empathize with patients on a deeper level while providing invaluable education to empower them to manage their conditions effectively.

As an active member of several esteemed medical organizations, including:

• 
  The American Academy of Allergy, Asthma, and Immunology
• The American College of Asthma, Allergy and Immunology
• The Texas Allergy, Asthma, and Immunology Society
• The Greater Houston Allergy Society, the Texas Medical Association

and the Harris County Medical Society

Dr. An Nguyen remains at the forefront of advancements in her field. Dr. An Nguyen’s expertise extends beyond her Internal Medicine and Allergy/Immunology certifications. She caters to adult and pediatric patients, ensuring comprehensive care for the entire family. Driven by a passion for serving diverse communities, she is fluent in both Spanish and Vietnamese. When asked about her motivation to become an allergist, Dr. Nguyen shared, “I chose to become an allergist because it allows me to work with patients of all ages and address a wide range of medical issues associated with immune system dysregulation.”

Reflecting on her favorite aspect of her profession, Dr. An Nguyen highlighted her joy in collaborative problem-solving with her patients and witnessing their progress toward better health. Dr. Nguyen emphasizes the importance of seeking specialized care from an allergy specialist to address allergy and asthma symptoms. By identifying specific triggers, or their absence, allergists can develop targeted diagnostic and treatment plans, ultimately reducing the reliance on surgical interventions in chronic sinus disease and minimizing medication side effects and asthma attacks. Outside of her professional commitments, Dr. Nguyen embraces an active lifestyle. She enjoys road biking, hiking, rock climbing, and exploring different cultures through travel alongside her husband. Additionally, Dr. Nguyen is an avid food enthusiast and delights in the culinary arts. She also cherishes the companionship of her feline friend, whose affection she has earned.

About McGovern Allergy & Asthma Clinic

McGovern Allergy & Asthma Clinic is a leading healthcare provider dedicated to delivering exceptional and comprehensive allergy and asthma care to patients of all ages in Houston, Texas since 1956. With a commitment to excellence, their team of highly skilled and compassionate allergists and immunologists remains at the forefront of medical advancements, ensuring patients receive personalized treatment plans and the most effective solutions available. From accurate diagnosis to ongoing care and education, the clinic is devoted to improving the lives of those affected by allergies and respiratory conditions in the Houston community and beyond.

To schedule an appointment with Dr. An Nguyen or to learn more, please call McGovern Allergy & Asthma Clinic at 713-469-3278 or visit https://www.mcgovernallergy.com/

Share article on social media or email:

SignatureCare Emergency Center, Houston, TX

Our current CDC guidance is that symptomatic individuals who test positive should stay home the first 5 days from initial symptom onset. Following that, they should wear masks for days 6-10 of the illness.

HOUSTON (PRWEB)
August 10, 2023

This week, SignatureCare Emergency Center reported an uptick in the number of patients coming into its Texas emergency rooms with COVID-19 symptoms.

SignatureCare owns and manages 20 emergency room locations throughout Texas, including nine in Houston area. Other emergency rooms are located in Atascocita/Humble, Spring, College Station/Bryan, Lewisville, Odessa, Paris, Austin, Pflugerville, Texarkana, Midland, and Killeen.

According to Dr. Chris Langan, SignatureCare’s Chief Operating Officer (COO), the company expects the upward trend to continue as the school year begins.

“We have been seeing a slight uptick in COVID cases, and we expect to see more as the school year begins. The COVID mortality rate still remains at an all-time low,” he said this week.

He cautioned Texans to follow current guidelines from the Centers for Disease Control and Prevention (CDC) if they believe they may have contracted COVID-19.

“Our current CDC guidance is that symptomatic individuals who test positive should stay home the first 5 days from initial symptom onset. Following that, they should wear masks for days 6-10 of the illness,” Dr. Langan said.

He added that there is no need to get a COVID-19 test if you are not showing symptoms, but if you decide to test and your result comes back positive, then you should take steps immediately to avoid spreading the virus.

“Asymptomatic individuals should not be getting tested for COVID. However, if you are asymptomatic and for some reason did a COVID test and are positive, please wear a mask for 5 days and monitor yourself for any respiratory symptoms,” he continued.

The CDC said this week that the incidence of COVID-19 in Texas is still relatively low but told residents to take precautionary measures to avoid contracting the virus.

“Stay up to date with COVID-19 vaccines, maintain ventilation improvements, avoid contact with people who have suspected or confirmed COVID-19, follow recommendations for isolation if you have suspected or confirmed COVID-19, and follow the recommendations for what to do if you are exposed to someone with COVID-19.

“If you are at high risk of getting very sick, talk with a healthcare provider about additional prevention actions. People may choose to mask at any time. People with symptoms, a positive test, or exposure to someone with COVID-19 should wear a high-quality mask or respirator when indoors in public,” the CDC said.

According to the latest CDC estimates, EG.5, a spinoff of the XBB recombinant strain of Omicron, is causing about 17% of new Covid-19 cases in the country, compared with 16% for the next most common lineage, XBB.1.16.

If you believe you may have been exposed to COVID-19 or you test positive for the virus, visit a nearby SignatureCare Emergency Center. Our ERs are open 24 hours, including during the holidays.

About SignatureCare Emergency Center

Houston, TX-based SignatureCare Emergency Center owns 24-hour emergency centers throughout Texas, including nine ER locations in the Houston area (Montrose, Houston Heights, Cypress/FM 1960, Copperfield, Memorial City, Westchase, Bellaire, Mission Bend/Sugar Land, and Stafford), Atascocita/Humble, Killeen, Austin, College Station/Bryan, Paris, Midland, Odessa, Pflugerville, Texarkana, Spring, and Lewisville, TX.

Share article on social media or email:

Dr. Ronald Ford, chief medical officer at Joe DiMaggio Children’s Hospital, greets Memorial Healthcare System CEO Scott Wester

“An engaged workforce will be a difference-maker at a time consumers are seeking convenient health solutions best delivered by a partner with a mission to serve the community, not shareholders.” – K. Scott Wester, Memorial Healthcare System CEO

HOLLYWOOD, Fla. (PRWEB)
August 10, 2023

A year into his tenure as president and CEO of Memorial Healthcare System (MHS), K. Scott Wester is making significant progress accomplishing short-term goals and setting a longer term strategic direction for what he calls ‘a complex business that’s part of a complex industry in a very large and diverse market.’

His vision comes from an understanding of the changing landscape for health and care providers and that a pre-COVID approach to doing business is no longer viable. Wester has Memorial hyper-focused on increasing access for South Florida communities and enhancing the consumer experience at destinations that include soon-to-be-opened urgent and/or primary care centers in northwest Miami-Dade County, Weston, and Plantation, a comprehensive cancer center in Pembroke Pines, and an expanded mobile program that is bringing primary care services to underserved audiences in Hallandale Beach, Miramar, Dania Beach, and Hollywood.

“We’ve been an integral part of the South Florida community for 70 years and the Memorial way and culture that’s been established will be the foundation of our success moving forward,” said Wester. “An engaged workforce will be a difference-maker at a time consumers are seeking convenient health solutions best delivered by a partner with a mission to serve the community, not shareholders.”

Wester leads an organization of more than 15,000 employees that features a patient and family-centered approach that is equally adept at delivering proactive expertise, services, and resources as it is reactive care. That’s resonated with consumers whose feedback resulted in Memorial being named the 18th most trusted healthcare brand in America in a recent report (“Humanizing Brand Experience”) from Monigle, one of the country’s largest, independent brand consultancies. That firm’s survey of more than 25,000 consumers also ranked MHS the fourth best system in the U.S. at empowering individuals with the information and resources to manage their health independently.

To bolster the dedicated team of caregivers that help Memorial prioritize the individual and family, Wester’s plan places a significant emphasis on workforce development to attract and retain the best talent. The system set a record for new hires during the CEO’s first year, including more than 70 physicians, and decreased overall year over year turnover from 21% to 14%. He has also connected with leaders at South Florida colleges and universities to help align degree programs and employment opportunities in a Memorial environment named one of Modern Healthcare magazine’s “2023 Best Places to Work in Healthcare.”

Understanding there is much more work to be done, Wester began his second year with an aggressive plan to expand services that will include:

• An $88 million infrastructure upgrade at Memorial Regional Hospital in Hollywood to construct a new Family Birthplace and upgrade its trauma center and emergency department.
• Development of approximately eight acres of land Memorial recently purchased at the corner of Hollywood Boulevard and State Road 7. Previously part of the footprint of the Hollywood Fashion Center, current conversation focuses on a mixed-use, health and wellness hub that will serve the area.

Looking back on the year gone by, Wester says the keys to early success were his ability to build relationships, willingness to collaborate with strategic partners, and a laser focus on value-based care that focuses more on the quality of patient outcomes than the quantity of services provided.

# # #

South Florida-based Memorial Healthcare System (http://www.mhs.net) is a national leader in quality care and patient, physician, and employee satisfaction. Its commitment to deeper caring and smarter health prioritizes a person-centered approach that has delivered safe, positive outcomes for 70 years.

Featuring multi-disciplinary collaboration, research, innovation, and transparency within its

many facilities, Memorial is focused on removing barriers, increasing access, and providing equitable care throughout the region. It employs a staff of more than 15,000 and operates six hospitals, numerous primary, urgent, and 24/7 care facilities, medical office buildings, a

health specialty center, and nursing home.

To learn more, visit mhs.net and connect on Facebook, X (formerly Twitter), Instagram, YouTube, and LinkedIn.

Share article on social media or email:

FF Biotherapeutics

JUPITER, Fla. (PRWEB)
August 10, 2023

An upcoming episode of Advancements with Ted Danson will focus on breakthroughs in personalized medicine.

This segment will explore how innovations in science and technology are revolutionizing healthcare, while providing elevated patient outcomes for a brighter future. With a look at FF Biotherapeutics, audiences will learn how a dedication to innovative and personalized therapies are pioneering a new era in healthcare.

Viewers will see how through collaborative advancements, global reach, and patient-centric innovation, FF Biotherapeutics is working to empower hope, healing, and a healthier tomorrow.

“Our approach is rooted in innovation and boundless thinking. We understand that true advancement doesn’t come from merely building on existing ideas but requires a willingness to explore uncharted territory. By refusing to be confined by traditional bottom-up strategies, we are pioneering a healthcare landscape where hope, healing, and a healthier tomorrow are not just goals but realities. It’s not just about the medicine; it’s about envisioning and creating a future where every patient is empowered to live their fullest life,” said Dr. Scott N. Freeman, PhD, CEO, FF Biotherapeutics.

The show will also explore how breakthroughs in groundbreaking research and therapeutic solutions are driving positive change and shaping the future of healthcare.

“We are excited to share how developments in healthcare are reshaping treatment paradigms for transformative patient outcomes,” said James Patterson, senior producer for the Advancements series.

About FF Biotherapeutics:

FF Biotherapeutics is dedicated to pioneering a new era in healthcare where innovative and personalized therapies lead the way in transforming patient outcomes and reshaping treatment paradigms. Its unyielding commitment to patients drives FF Biotherapeutics to empower hope, healing, and a healthier tomorrow for individuals facing serious diseases worldwide. Through innovative thinking, adapting new methodologies, promising technologies, and patient-centric innovation, FF Biotherapeutics aims to be at the forefront of groundbreaking research and therapeutic solutions, driving positive change and shaping the future of healthcare.

For more information, visit: https://www.ffbiotherapeutics.com/.

About Advancements and DMG Productions:

Advancements is an information-based educational television series that explores recent developments taking place across several industries and economies. Shining a light on important issues and topics impacting society today, the series features the cutting-edge improvements, state-of-the-art technologies, and innovative solutions responsible for shaping, molding, and transforming our world.

Backed by experts in various fields, DMG Productions is dedicated to education and advancement, and to consistently producing commercial-free, educational programming for viewers and networks.

For more information, please visit http://www.AdvancementsTV.com or call 866-496-4065.

Share article on social media or email: